MedWatch

Genmab in potential million-dollar-deal with US company

The Danish company Genmab has signed a new deal for a potential value of hundreds of millions of dollars, according to which they will supply antibodies to an American biotech company.

Foto: Genmab / PR

If things work out, the Danish company Genmab could earn just about a billion Danish kroner from the recently signed deal with the US company Janssen Biotech.

The deal concerns Genmab’s DuoBody-technology platform, which the company will use to create panels of bispecific antibodies against various disease target combinations identified by Janssen, who will fully finance Genmab’s development work.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier